Yi‐Lin Chiu

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 840 citations · Full text

Hematological Malignancy, Medicine, Malignant Blood Disorder +11

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

Leena Gandhi, D. Ross Camidge, Moacyr Oliveira et al. · Journal of Clinical Oncology · 2011 · 579 citations · Full text

The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food Effect

Cheri E. Klein, Yi‐Lin Chiu, Walid M. Awni et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2007 · 151 citations

Diminished Food Effect, Pharmaceutical Science, Ritonavir Exposures +13

Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease

Yi‐Lin Chiu, David T. Rubin, Séverine Vermeire et al. · Inflammatory Bowel Diseases · 2013 · 122 citations · Full text

A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen

Margaret Johnson, Joseph Gathe, Daniel Podzamczer et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2006 · 118 citations